SAKK auf dem European Society for Medical Oncology (ESMO) Congress 2022
SAKK 08/14: Mini-oral presentation
«IMPROVE Investigation of metformin in patients with castration resistant prostate cancer in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial»
Coordinating Investigator
SAKK 08/14, Presentation ESMO 2022
SAKK 08/14 - IMPROVE Investigation of metformin in patients with castration resistant prostate cancer in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
SAKK 41/16: Poster
Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP)
Coordinating Investigator
SAKK 41/16, Poster ESMO 2022
Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16
SAKK 57/16: Poster
SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up
Coordinating Investigator
SAKK 57/16, Poster ESMO 2022
SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up
23. September 2022